Major FoB Collaborations [Added geography column and several new footnotes.] Items are shown in reverse chronological order. [pre] Date Targets Geography iHub References Catalent-UMN 12/12 various Asia #msg-82556713 Merck KGaA-RDY 6/12 oncology global #msg-76359649 Daiichi-Coherus 5/12 * Asia #msg-75397629 Fujifilm-Kyowa 3/12 Humira not specified #msg-73800486 ACT-Bioton 2/12 insulin US & Europe #msg-74987123 ACT-AMGN 12/11 † global #msg-70097496, #msg-84340328 BAX-MNTA 12/11 various‡ global #msg-70212854, #msg-70258421 Samsung-BIIB 12/11 @ not specified #msg-69629103 MRK-Hanwha 6/11 Enbrel global** #msg-64164954, #msg-64193403 MYL-Biocon 6/09 x global #msg-39119393, #msg-72421544 TEVA-Lonza 1/09 y global #msg-34930012 Procognia-UTR n/a Humira not specified #msg-84340976[/pre]*Enbrel and Rituxan. **US presumably excluded due to AMGN’s long-lasting patent protection. †Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs. ‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually. @ Rituxan program terminated (#msg-80622249); status of other programs unknown; presumably excludes FoB’s for BIIB’s branded drugs. x Six products: Herceptin, Neulasta, Avastin, Humira, Enbrel, one undisclosed. y Rituxan program terminated (#msg-80236315); status of other programs unknown.